Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 46Recurrence 6Leukemia, Myeloid, Acute 5Waldenstrom Macroglobulinemia 2Smoldering Multiple Myeloma 2Plasmacytoma 2Lymphoma, Large B-Cell, Diffuse 2Immunoglobulin Light-chain Amyloidosis 2Carcinoma, Non-Small-Cell Lung 2Various Advanced Cancer 1Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Microsatellite Unstable Colorectal Cancer 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hypergammaglobulinemia 1Hodgkin Disease 1Amyloidosis 1

Interventions

Rituximab 155Cyclophosphamide 120fludarabine phosphate 71Whole-Body Irradiation 55Mycophenolic Acid 54Etoposide 53Peripheral Blood Stem Cell Transplantation 46fludarabine 45Melphalan 44Granulocyte Colony-Stimulating Factor 43Busulfan 43Tacrolimus 39Filgrastim 37Vincristine 33Cyclosporine 31Bendamustine Hydrochloride 31Prednisone 29Doxorubicin 29Antilymphocyte Serum 28Methotrexate 27Cytarabine 27Lenalidomide 23Carmustine 22Bortezomib 22plerixafor 20Dexamethasone 19Thiotepa 17Stem Cell Transplantation 17Radiotherapy 17tositumomab I-131 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Non-Hodgkin × daratumumab × Clear all
NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Bristol-Myers Squibb

Phase 1/2 Completed
320 enrolled 35 charts
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡